|
RIUNIONE MONOTEMATICA A.I.S.F. 2009 Epatocarcinoma: eziologia, meccanismi molecolari e nuovi approcci diagnostico-terapeutici Thursday, May 7th SESSION I - Epidemiology
Chairpersons: G.B. Gaeta - L. Pagliaro
08.30-08.45 Epidemiology: the current scenario - F. Trevisani
08.45-09.00 Identification of risk patients - A. Sangiovanni
The clinician’s view
09.00-09.20 Is HCC mortality reduced by screening? - M. Colombo
09.20-09.30 Discussion SESSION II - Molecular and pathological pathways (part 1)
Chairpersons: M. Levrero - G. Raimondo
09.30-09.50 Inflammation and fibrogenesis - F. Marra
09.50-10.05 Angiogenesis - M. Parola
10.05-10.20 miRNA - L. Gramantieri
10.20-10.45 Coffee Break SESSION II - Molecular and pathological pathways (part 2)
Chairpersons: C. Ferrari - M. Mondelli
10.45-11.00 Epigenetics - D. Calvisi
11.00-11.15 Immunoproteomics - V. Barnaba
11.15-11.35 Will molecular studies improve our working attitude towards HCC? - M. Levrero
11.35-11.50 Discussion
11.50-12.10 Chairpersons: A. Alberti - R. Labianca
Lecture: Oncogenomics: from tools to applications - J. Zucman-Rossi
12.10-12.40 A.I.S.F. General Assembly
12.40-13.40 Satellite Symposium I
13.40-14.15 Lunch and poster view SESSION III - A.I.S.F. Oral Communications
Chairpersons: A.I.S.F. Coordinating Committee SESSION IV - Viruses, metabolic disorders and HCC
Chairpersons: F. Bonino - A. Pietrangelo
15.00-15.15 HBV - T. Pollicino
15.15-15.30 HCV - C. Balsano
15.30-15.45 Insulin resistance and metabolic syndrome - G. Svegliati Baroni
The clinician’s view
15.45-16.05 Can we prevent HCC? - G. Raimondo
16.05-16.20 Discussion
16.20-16.45 Coffee Break SESSION V - A.I.S.F. Oral Communications
Chairpersons: A.I.S.F. Coordinating Committee Friday, May 8th SESSION VI - Diagnosis and staging
Chairpersons: S. Bruno - A. Gasbarrini
08.40-09.05 Advances in pathological diagnosis - T. Roskams
09.05-09.25 Advances in Imaging Techniques: CT and MRI - G. Brancatelli
09.25-09.40 Advances in Imaging Techniques: CEUS - L. Solbiati
09.40-10.00 Staging and prognosis - A. Grieco
The clinician’s view
10.00-10.20 How to make diagnosis of HCC in 2009 - L. Bolondi
10.20-10.40 Discussion
10.40-11.15 Coffee Break SESSION VII - A.I.S.F. Oral Communications
Chairpersons: A.I.S.F. Coordinating Committee
12.30-13.30 Satellite Symposium III
13.30-14.10 Lunch and poster view SESSION VIII - Current treatments: technique and results
Chairpersons: M. Colombo - G. Navarra
Surgery and locoregional treatments
14.10-14.30 Surgical resection (including laparoscopic approaches) - U. Cillo
14.30-14.45 Percutaneous ablation: current and future tools - F. Brunello
14.45-15.00 Endoarterial treatments TACE and DC-BEADS - A. Nicolini
15.00-15.15 Internal radioembolization - R. Golfieri
15.15-15.35 Discussion
Chairpersons: M. Angelico - M. Colledan
The radiologist’s view
15.35-16.00 Imaging for the assessment of treatment efficacy (RFA/PEI, TACE, antiangiogenic agents) - R. Lencioni
16.00-16.25 Coffee Break
Chairpersons: M. Angelico - M. Colledan
Transplantation
16.25-16.40 How bridging patient with HCC to transplantation - M. Pompili
16.40-16.55 Graft allocations for HCC patients - A.D. Pinna
16.55-17.20 Milan criteria: pro and cons - M. Schwartz
17.20-17.35 Discussion
Chairpersons: L. Bolondi - A. Santoro
Systemic therapies: current status and perspectives
17.35-17.50 Sorafenib as the current standard for advanced HCC - F. Farinati
17.50-18.15 New drugs in the pipeline: phase II and beyond - B. Daniele
18.15-18.30 Immunotherapeutic approaches - G. Missale
The clinician’s view
18.30-18.50 Looking for the ultimate aim of treatment - A. Craxì
18.50-19.00 Discussion Saturday, May 9th SESSION IX - A.I.S.F. Oral Communications
Open issues in guidelines for HCC
Chairpersons: A. Craxì - P. Pontisso
09.15-09.30 Definition of subgroups in intermediate stage BCLC-B - C. Cammà
09.30-09.45 Variability of TACE procedures and schedule of treatment - M. Grosso
09.45-10.00 How to treat HCC in Child-Pugh class B patients? - F. Piscaglia
10.00-10.10 Discussion
10.10-10.40 Coffee Break
Chairpersons: G.L. Rapaccini - R. Mazzanti
10.40-10.55 Setting of new interventional radiological procedures in the appropriate clinical scenario - R. Lencioni
10.55-11.10 Treatment of preneoplastic lesions: strength of the rationale - M. Borzio
11.10-11.25 When resection is the best option? Shall we keep fixed to guidelines for resection? - B. Gridelli
11.25-11.50 The impact of current guidelines in the actual clinical scenario - L. Bolondi
11.50-12.00 ECM Quiz and Closure
|
